Document:

Fourth Amendment to Share Surrender Agreement, dated as of August 7, 2012

 Exhibit 10.1 
 FOURTH AMENDMENT TO 
 SHARE SURRENDER AGREEMENT 

This Fourth Amendment to the Share Surrender Agreement (the “Fourth Amendment”) is made and entered into as of August 7,
2012, by and between The PNC Financial Services Group, Inc., a Pennsylvania corporation (“PNC”), BlackRock, Inc., a Delaware corporation (“BlackRock”) and PNC Bancorp, Inc., a Delaware corporation and indirectly wholly owned
subsidiary of PNC (“Bancorp”) (as successor to PNC Asset Management, Inc., a Delaware corporation (“PAM”) under an Assignment and Assumption Agreement entered into as of January 14, 2005 (the “Assignment and Assumption
Agreement”) to the Share Surrender Agreement (as amended, the “Share Surrender Agreement”)), dated as of October 10, 2002. Capitalized terms used in this Fourth Amendment and not defined have the meanings set forth in the Share
Surrender Agreement. 
 RECITALS 
 Pursuant to the Share Surrender Agreement, PAM has agreed to surrender and make available for long-term retention and incentive programs 4,000,000 shares of BlackRock Common and Series C Preferred Stock
(together, “BlackRock Stock”). To date, Bancorp has surrendered an aggregate of 2,482,763 shares of BlackRock Stock to BlackRock in accordance with the Share Surrender Agreement. (The number of shares of BlackRock Stock equal to 4,000,000
shares minus the number of shares of BlackRock Stock surrendered in accordance with the Share Surrender Agreement shall be deemed the “Remainder Shares.”) 
 BlackRock, Bancorp and PNC now desire to clarify (i) the maximum number of Remainder Shares that may be funded on by Bancorp annually pursuant to the Share Surrender Agreement for Future Incentive
Plans, and (ii) that the theoretical expense associated with awards forfeited at any time prior to their settlement or expiration may be reallocated to awards already issued or to new awards. 

Accordingly, the parties to this Fourth Amendment agree, notwithstanding anything in the Share Surrender Agreement to the contrary, as
follows: 

 1. Agreement as to Annual Funding Caps. The parties agree that BlackRock’s use
of Remainder Shares during each annual period beginning with 2012 shall be limited such that PNC will not recognize in the aggregate more than $50 million in pre-tax expense in any one year (each an “Annual Funding Cap”) as a result of the
use of such Remainder Shares as provided for in Section 1.2(b) of the Share Surrender Agreement, provided that the following adjustments to the method of calculation in Section 1.2(b) shall be made: 

 

	 	(i)	For the purposes of Clause (1)(y) of Section 1.2(b), “PNC’s ownership percentage in BlackRock” shall be the percentage ownership that would be
used to determine PNC’s recognition of BlackRock’s income under equity method accounting principles regardless of whether the equity method of accounting is used by PNC with respect to its holdings in BlackRock at such time; and

  

	 	(ii)	For the purposes of Clause (2) of Section 1.2(b), the “pre-tax expense directly recognized by PNC” shall be the theoretical expense applicable to
the annual period that would be recognized by multiplying BlackRock’s per share book value times the number of Remainder Shares to be granted during the annual period divided by the vesting period; provided that forfeitures may be credited and
reallocated in accordance with Paragraph 2 below of this Fourth Amendment. 

 2. Credit for Forfeitures;
Ability to Reallocate or Use for New Awards. The expense related to Remainder Shares that is originally recognized in calculating each Annual Funding Cap with respect to any awards that are subsequently forfeited prior to their respective
settlement or expiration shall be credited toward the aggregate funding availability under the applicable Annual Funding Cap and such expense may be reallocated to awards already issued during such annual award period (even if the forfeiture is
subsequent to such period), or to awards to be issued during such period (in the event the forfeiture is prior to the end of such period). The amount used in calculating such credit shall equal the amount charged toward the Annual Funding Cap in
connection with its initial grant in accordance with Section 1.2(b) of the Share Surrender Agreement as amended by this Fourth Amendment and not the then current fair market, book or any other value of any such Remainder Shares. Similarly, for
the avoidance of doubt, when reallocating any credit resulting from a forfeiture to an award already outstanding, the expense that would have been recognized in connection with its initial grant shall be used as the charge against the remaining
funding availability under the respective Annual Funding Cap and not the then current fair market, book or other value of the outstanding award. 
 3. Other Awards; No Other Amendments. Nothing in this Fourth Amendment or the Share Surrender Agreement is intended to limit any awards that may be made by BlackRock that are not intended to be
funded by Bancorp pursuant to the Share Surrender Agreement. Except as expressly amended by this Fourth Amendment, the Share Surrender Agreement shall remain in full force and effect in accordance with its terms. For the avoidance of doubt, nothing
in this Fourth Amendment is intended to reduce the total number of Remainder Shares available for the funding of Future Incentive Plans or to amend, restrict or limit the obligations of PNC and Bancorp to fund Future Incentive Plans with Remainder

 
Shares following the Third Award Period, pursuant to the terms of the Share Surrender Agreement, in a total amount equal to the 4,000,000 shares agreed to in the Share Surrender Agreement.

 4. Counterparts. This Fourth Amendment may be executed in two or more counterparts, all of which shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each of the parties and delivered to the other party, it being understood that each party need not sign the same counterpart. 

IN WITNESS WHEREOF, the parties have duly executed this Fourth Amendment as of the date first above mentioned. 

 

					
	BLACKROCK, INC.
		
	 By: 
	 	 /s/ Joseph Feliciani

	 Name:
	 	 Joseph Feliciani

	 Title:
	 	 Managing Director

	
	 PNC BANCORP, INC.

		
	 By: 
	 	 /s/ George P. Long, III

	 Name:
	 	 George P. Long, III

	 Title:
	 	 Assistant Secretary

	
	 THE PNC FINANCIAL SERVICES GROUP, INC.

		
	 By: 
	 	 /s/ George P. Long, III

	 Name:
	 	 George P. Long, III

	 Title:
	 	 Corporate SecretaryEX-10.1

 Exhibit 10.1 

 

			
	

 	  	 10390 Pacific Center Court, San Diego, CA 92121
 858•646•1100, FAX: 858•646•1151
 www.vical.com

 CONSULTING AGREEMENT 
 FOURTH AMENDMENT 
 This Fourth Amendment, to the Consulting Agreement (the “Fourth
Amendment”), is made effective as of June 30, 2012 (the “Fourth Amendment Effective Date”) and is entered into by and between Vical Incorporated (“Vical”), a Delaware Corporation, having a place of business at 10390
Pacific Center Court, San Diego, CA 92121-4340 and Gary A. Lyons (the “Consultant”), an individual having a principal address of 1344 Stratford Court, Del Mar, CA 92014. 
 Whereas, Vical and Consultant entered into a Consulting Agreement (the “Agreement”), effective August 1, 2010 which has been further amended thereby extending the Term until June 30,
2012; 
 Whereas, Vical and Consultant wish to further amend the Agreement to extend the Term until December 31, 2012; 

Now, therefore, in consideration of the covenants and promises contained herein, the parties agree as follows: 

Exhibit A of the Agreement, as previously amended, is hereby amended to be replaced in its entirety as follows: 

 

	Term:	This Agreement shall terminate on December 31, 2012, unless renewed in a writing signed by both parties for an additional six (6) months. Either party
shall have the right to terminate this Agreement at any time with thirty (30) days’ written notice to the other party. 

Except as amended hereby, all other terms and conditions of the Agreement shall remain unchanged and shall continue in full force and effect. 

In witness whereof, the parties have executed this Fourth Amendment to the Consulting Agreement as of the last day indicated below. 

 

									
	Vical Incorporated	 		 	Gary A. Lyons
					
	By:	 	/s/ Jill M. Broadfoot	 		 		 	
					
	Name:	 	Jill M. Broadfoot	 		 	By:	 	/s/ Gary A. Lyons
					
	Title:	 	Senior Vice President & CFO	 		 	Name:	 	Gary A. Lyons
					
	Date:	 	6/18/12	 		 	Date:	 	6/19/12EX-10.3

 Exhibit 10.3 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. 
 1ST AMENDMENT to
U.S. LICENSE AGREEMENT BETWEEN 
 VICAL INCORPORATED AND ASTELLAS PHARMA INC. 

THIS AMENDMENT is made and entered into as of August 6, 2012 (“Amendment Effective Date”) by and
between VICAL INCORPORATED, a Delaware corporation (“Vical”), having an address of 10390 Pacific Center Court, San Diego, California, 92121, USA, and
ASTELLAS PHARMA INC., a company organized under the laws of Japan (“Astellas”), having an address of 3-11, Nihonbashi-Honcho 2-chome, Chuo-Ku, Tokyo 103-8411, Japan.

 RECITALS 
 WHEREAS, the parties have entered into the U.S. License Agreement dated July 12, 2011 (the “U.S. License Agreement”); and 

WHEREAS, the parties wish to amend certain payment provisions in the U.S. License Agreement as set forth herein. 

NOW, THEREFORE, for and in consideration of mutual covenants and the premises herein contained, the parties,
intending to be legally bound, hereby agree as follows: 
 AGREEMENT 

 

	A.	INTERPRETATION 

 Unless otherwise
defined in this Amendment, the definitions of the U.S. License Agreement shall be also applicable to this Amendment. 
 Except as
specifically amended by this Amendment, the terms and conditions of the U.S. License Agreement shall remain in full force and effect. 
  

	B.	MILESTONE PAYMENTS 

 Subject to
Section C of this Amendment, Section 5.2 of the U.S. License Agreement shall be amended as follows: 
 “5.2
Milestone Payments. Within thirty (30) days after the occurrence of each of the following milestone events, Astellas shall pay to Vical the corresponding non-refundable and non-creditable (unless otherwise set forth in this Section)
milestone payment set forth below (whether such milestone event is achieved by Astellas or any Sublicensee): 
  

					
	 Milestone Event
	  	Milestone Payment	 
	 [...***...]
	  	US$	[...***...	] 
	 [...***...]
	  			

  

					
		  	1	  	***Confidential Treatment Requested

					
	 Milestone Event
	  	Milestone Payment	 
	 [...***...]
	  	US$	[...***...	] 
	 [...***...]
	  			
	 [...***...]
	  			

  

					
		  	2	  	***Confidential Treatment Requested

					
	 Milestone Event
	  	Milestone Payment	 
	 [...***...]
	  			
	 [...***...]
	  	US$	[...***...	] 
	 [...***...]
	  	US$	[...***...	] 

  

					
		  	3	  	***Confidential Treatment Requested

					
	 Milestone Event
	  	Milestone Payment	 
	 [...***...]
	  	US$	[...***...	] 
	 [...***...]
	  			
	 [...***...]
	  			

  

					
		  	4	  	***Confidential Treatment Requested

 Each of the milestone payments described in this Section 5.2 shall be payable one time
for the first achievement of such milestone event by any applicable Product, regardless of the number of other Products that subsequently achieve such milestone event. For clarification, in the event two or more milestone events are achieved at the
same time, the milestone payments for both milestone events shall be due.” 
  

	C.	FURTHER AMENDMENT FOR MILESTONE PAYMENT 

 It is recognized and agreed by the parties that the amended Section 5.2 pursuant to Section B above (“Amended 5.2”) is based on [...***...] If [...***...], Amended 5.2 shall
automatically be further amended as follows: 
 “5.2 Milestone Payments. Within thirty (30) days after the
occurrence of each of the following milestone events, Astellas shall pay to Vical the corresponding non-refundable, non-creditable milestone payment set forth below (whether such milestone event is achieved by Astellas or any Sublicensee):

  

					
	 Milestone Event
	  	Milestone Payment	 
	 [...***...]
	  	US$	[...***...	] 
	 [...***...]
	  	US$	[...***...	] 
	 [...***...]
	  			

  

					
		  	5	  	***Confidential Treatment Requested

					
	 Milestone Event
	  	Milestone Payment	 
	 [...***...]
	  			
	 [...***...]
	  			
	 [...***...]
	  	US$	[...***...	] 

  

					
		  	6	  	 ***Confidential Treatment Requested

					
	 Milestone Event
	  	Milestone Payment	 
	 [...***...]
	  	US$	[...***...	] 
	 [...***...]
	  			
	 [...***...]
	  			

 Each of the milestone payments described in this Section 5.2 shall be payable one time for the first
achievement of such milestone event by any applicable Product, regardless of the 

  

					
		  	7	  	 ***Confidential Treatment Requested

 
number of other Products that subsequently achieve such milestone event. For clarification, in the event two or more milestone events are achieved at the same time, the milestone payments for
both milestone events shall be due.” 
 For the purpose of this Amendment, such further amended Section 5.2 shall be
referred to as “Original 5.2”. 
  

	D.	ADJUSTMENT 

 Within ninety
(90) days following the date when [...***...]: 
  

	 	(i)	[...***...]; 

  

	 	(ii)	[...***...]; or 

  

	 	(iii)	[...***...]. 

 For
avoidance of doubt, (i) [...***...] and (ii) [...***...]. 
 In the event that [...***...]. In such
case, in the event that [...***...] 

  

					
		  	8	  	 ***Confidential Treatment Requested

 
[...***...]. In case that [...***...]. In the event that [...***...]. In case that [...***...]; provided, however, consistent with the [...***...]. 

 

	E.	ROYALTY RATE 

Section 5.3(a) of the U.S. License Agreement shall be amended as follows: 

“(a) Royalty Rate. Astellas shall pay Vical royalties as calculated by multiplying the applicable royalty rates by the
corresponding amount of incremental Net Sales in the Territory in a Fiscal Year. 
  

					
	 Net Sales in the Territory Per Fiscal Year
	  	Royalty Rate	 
	 Portion less than or equal to US$[...***...]
	  	 	[...***...	]% 
	 Portion greater than US$[...***...] and less than or equal to US$[150,000,000]
	  	 	[...***...	]% 
	 Portion greater than US$ [...***...]
	  	 	[...***...	]% 

 By way of example, [...***...]: 

  

					
		  	9	  	 ***Confidential Treatment Requested

 [...***...] 
 [...***...] 
 [...***...] 

 
  

[...***...] 
 In same example, [...***...]: 
  

									
	 	  	 [...***...]
	  	 [...***...]
	  	 [...***...]
	  	 [...***...]

					
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
					
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

   ” 
  

	F.	DEFINITION 

 The following
sentences shall be inserted in appropriate places in Article 1 of the U.S. License Agreement. 
 “1.19-A
“[...***...]” shall have the meaning provided in Section [...***...].” 
 “1.31-A
“Fiscal Year” shall have the period starting from April 1 of certain Calendar Year and ending at March 31 of the following Calendar Year.” 
 “1.34-A “[...***...]” shall have the meaning provided in Section [...***...].” 

 

	G.	DURATION OF THE AMENDMENT 

 The
term of this Amendment shall commence on the Amendment Effective Date and, unless otherwise agreed in writing between the parties, continue until the date of expiration or earlier termination of the U.S. License Agreement. 

  

					
		  	10	  	 ***Confidential Treatment Requested

 IN WITNESS WHEREOF, the parties hereto have duly
executed this AMENDMENT as of the date set forth below. 
  

									
	VICAL INCORPORATED	 		 	ASTELLAS PHARMA INC.
					
	By:	 	 /s/ Vijay B. Samant
	 		 	By:	 	 /s/ Yoshihiko Hatanaka

	Name:	 	Vijay B. Samant	 		 	Name:	 	Yoshihiko Hatanaka
	Title:	 	President and CEO	 		 	Title:	 	President and CEO
	Date:	 	August 6, 2012	 		 	Date:	 	August 2, 2012

  
 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}]]